On August 10, 2018 the US Food and Drug Administration (FDA) approved ONPATTRO™, a nanomedicine for treating the devastating and usually lethal hereditary illness known as hereditary transthyretin-induced amyloidosis (hATTR).
The approval of ONPATTRO™ has opened the door to a new era of gene therapies to treat most human diseases—including hereditary diseases, infectious diseases, chronic diseases and cancer—more effectively.
“It is just a matter of time.” This is the implication of a commentary published in the December 2019 issue of Nature Nanotechnology by the scientists and pharmaceutical experts behind the development of ONPATTRO™.
The senior author of the commentary is NMIN Scientific Director and CEO Dr. Pieter Cullis, whose laboratory contributed to the revolutionary lipid nanoparticle (LNP) delivery technology behind ONPATTRO’s success.